A message from our Chair
In 2014, ACTA was established to fill a gap between the people involved in delivering and supporting clinical trials, consumers, and those who are charged with making decisions on trials including governments, regulators, and funders.
The 2023-2024 financial year has seen us has continue to build on this decade of foundation to further advance the field of clinical trials through the delivery of a suite of activities most relevant to the current clinical trials environment.
As Chair, I have found it incredibly rewarding to see how our work has created greater connection. It has also been humbling to see our sector strengthen to ultimately see a positive shift in the impact trials are having for patients.
The changing health landscape continues to provide ongoing challenges in terms of growing rates of comorbidities and health complexities, an aging population, increased demand, limited funding, and workforce shortages.
To best support our members and the needs of the broader sector this year, we have delivered educational and networking experiences, developed and shared practical resources, evoked sector connection through our special interest and working groups, promoted the benefits of consumer engagement in trials, and worked directly with governments, agencies and stakeholders to advocate for our sector.
I hope you have directly reaped the benefits from these activities, and we are committed to building on this work even further in the years to come.
Prof Christopher Reid
ACTA Chair
During 2023-2024 we were proud to deliver:
16 events, webinars and workshops
connecting clinical researchers with governments, policy makers and consumers on issues that impact the conduct of investigator-initiated clinical trials across the Australian healthcare system.
